AbbVie (ABBV) will raise its quarterly dividend to $0.71 per share.

The cash dividend is payable February 15, 2018 to shareholders of record at the close of business on January 12, 2018. 

Since the company's inception in 2013, AbbVie has increased its dividend by more than 77 percent. The current dividend yield is 2.9%.

AbbVie Inc. is a research-based biopharmaceutical company. The company has business in four primary therapeutic areas: immunology, oncology, virology and neuroscience. AbbVie’s products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. Abbvie's Humira medicine (for treatment of psoriasis and rheumatoid arthritis) is the world's best selling prescription medicine.  AbbVie became an independent company as a result of the distribution by Abbott Laboratories of 100% of the outstanding common stock of AbbVie to Abbott’s shareholders.